DanaRizk United StatesUniversity of Alabama at Birmingham

DanaRizk
Dr Dana Rizk is Tenured Professor of Medicine in the Division of Nephrology at the University of Alabama at Birmingham (UAB). She also serves as Director of Clinical Trials Research in the Division of Nephrology and as Medical Director for the Clinical Trials Administrative Office (part of the CCTS) at UAB. She has a passion for education and has served as a member of the Clinical Competency Committees for the Internal Medicine as well as the Nephrology Programs. She is the recipient of several teaching awards. Her clinical and research interests revolve around glomerular diseases and, in particular IgA Nephropathy (IgAN). She has served as the site principal investigator on many clinical trials and is part of several multi-disciplinary translational research projects focused on the role of biomarkers in the diagnosis and prognosis of IgAN. Her research efforts have resulted in more than 60 peer-reviewed publications in prestigious medical journals including the New England Journal of Medicine.
Institution

Day 2 - Monday April 15, 2024

Time Session
3 p.m.
4 p.m.
LBCT
AlessiaFornoni Chairperson United StatesUniversity of Miami
MichelleRheault Chairperson rheau002@umn.eduUnited StatesUniversity of Minnesota
  • Predicting the Risks of Kidney Failure and Death in Adults With Moderate-to-severe Chronic Kidney Disease (KDpredict)
    PietroRavani Free Communication pravani@ucalgary.caCanadaUniversity of Calgary
  • Plasma Exchange in ANCA Associated Vasculitis GN: Update After Pexivas
    Wladimir MietekSzpirt Speaker wladimir.mietek.szpirt.01@regionh.dkDenmarkRigshospitalet, University of Copenhagen, Dept. of Nephrology, Denmark, Senior Research Consultant
  • EFFICACY AND SAFETY OF IPTACOPAN IN PATIENTS WITH IgA NEPHROPATHY: INTERIM RESULTS FROM THE PHASE 3 APPLAUSE-IgAN STUDY
    DanaRizk Free Communication drizk@uabmc.eduUnited StatesUniversity of Alabama at Birmingham
  • SPARSENTAN VS IRBESARTAN IN PATIENTS WITH IMMUNOGLOBULIN A NEPHROPATHY (IgAN): SUBGROUP ANALYSES OF 2-YEAR RESULTS FROM THE PIVOTAL PHASE 3 PROTECT TRIAL
    JonathanBarratt Free Communication United KingdomUniversity of Leicester, Leicester, UK
  • PREGNANCY AMONG WOMEN ON CHRONIC DIALYSIS : THE FRENCH COHORT
    CécileCouchoud Free Communication cecile.couchoud@biomedecine.frFranceREIN registry, Agence de la biomédecine, France
Hall A

Pre-Congress - Saturday April 13, 2024

Time Session
9 a.m.
11 a.m.
GN1
AdrianLiew Chairperson SingaporeMount Elizabeth Novena Hospital, Singapore
HeatherReich Chairperson CanadaUniversity of Toronto, University Health Network
HernánTrimarchi Chairperson ArgentinaHOSPITAL BRITÁNICO DE BUENOS AIRES
JonathanBarratt Chairperson United KingdomUniversity of Leicester, Leicester, UK
  • Histophysiology of the Glomerulus
    SoniaChicano Speaker sonialchicano@yahoo.comPhilippinesISN
  • Overview of Immunosuppression
    DanaRizk Speaker drizk@uabmc.eduUnited StatesUniversity of Alabama at Birmingham
  • Genetic Testing in Glomerular Diseases
    KeishaGibson Speaker keisha_gibson@med.unc.eduUnited StatesUniversity of North Carolina at Chapel Hill, USA
  • Approach to RPGN
    ArennJauhal Speaker Arenn.Jauhal@uhn.caCanada
  • Case Presentation and Discussion 1
    HernánTrimarchi Speaker ArgentinaHOSPITAL BRITÁNICO DE BUENOS AIRES
Hall E